跳至主要内容
临床试验/NCT06281210
NCT06281210招募中不适用

Non-inferiority Study in Patients With Complete Pathological Response After Neoadjuvant Chemotherapy and Negative VABB Biopsy Undergoing RT Alone, Omitting Surgical Treatment

European Institute of Oncology4 个研究点 分布在 1 个国家目标入组 77 人开始时间: 2023年12月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
77
试验地点
4
主要终点
Event-free survival

研究概览

简要总结

This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.

详细描述

Neoadjuvant chemotherapy (NACT) in breast cancer is considered the "gold standard" for the treatment of locally advanced and inoperable malignancies.

In recent years, in view of the evidence gathered, it has also become a conventional treatment alternative for patients with operable disease who are possible candidates for adjuvant chemotherapy. NACT thus aims to reduce mortality and increase surgical options, while at the same time allowing in vivo chemosensitivity testing. In view of this, NACT represents the ideal setting for clinical and translational research, which nowadays also has to address the question of future treatment options.

It is indeed a source of lively debate whether chemotherapy should be considered the only possible treatment option for the patient.

This study falls into this context, the innovative aim of which is to demonstrate histologically with the use of VABB, the complete pathological response (pCR) and to avoid surgery.

The main aim of this study is to show that a non-surgical, radiotherapy-only treatment and follow-up approach is not inferior to a surgical approach for patients who have shown complete pathological response (pCR) following neoadjuvant chemotherapy (NACT), as confirmed through histological analysis of imaging-guided sampling.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age> 18 years
  • infiltrating breast carcinoma, non-special histotype, triple negative or HER2 +, T1-T2 N0
  • single lesion
  • neo-adjuvant chemotherapy treatment for at least 12 weeks according to clinical practice
  • conservative surgery proposal
  • tumour bed identified by breast markers placed in pre NACT by radiologist

排除标准

  • Bilateral or multicentric tumour
  • Presence of microcalcifications visualised on mammography
  • Presence of associated DCIS
  • Positive history of previous breast cancer
  • Positive history of medical or psychiatric conditions preventing adherence to the protocol
  • High risk patient

结局指标

主要结局

Event-free survival

时间窗: 5 years

Absence of disease recurrence or progression, second primary tumor, or death

次要结局

  • Contrast-Enhanced Mammography (CEM) positive predictive value(6 months)
  • Positive predictive value of MRI(6 months)

研究者

发起方
European Institute of Oncology
申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验